| Literature DB >> 32090095 |
Akiko Kubomura1, Tsuyoshi Sekizuka2, Daisuke Onozuka3, Koichi Murakami4, Hirokazu Kimura5, Masahiro Sakaguchi6, Kazunori Oishi7, Shinichiro Hirai4, Makoto Kuroda2, Nobuhiko Okabe1.
Abstract
Class 1 integrons (c1-integrons) are associated with multidrug resistance in diarrheagenic Escherichia coli (DEC). However, little is known about gene cassettes located within these c1-integrons, particularly truncated c1-integrons, in DEC strains. Therefore, the aims of the present study were to reveal the relationship between antimicrobial resistance and the presence of truncated c1-integrons in DEC isolates derived from human stool samples in Japan. A total of 162 human stool-derived DEC isolates from Japan were examined by antimicrobial susceptibility testing, PCR-based gene detection, and next-generation sequencing analyses. Results showed that 44.4% (12/27) of c1-integrons identified in the DEC isolates harbored only intI1 (an element of c1-integrons) and were truncated by IS26, Tn3, or IS1-group insertion sequences. No difference in the frequency of antimicrobial resistance was recorded between intact and truncated c1-integron-positive DEC isolates. Isolates containing intact/truncated c1-integrons, particularly enteroaggregative E. coli isolates, were resistant to a greater number of antimicrobials than isolates without c1-integrons. aadA and dfrA were the most prevalent antimicrobial resistance genes in the intact/truncated c1-integrons examined in this study. Therefore, gene cassettes located within these intact/truncated c1-integrons may only play a limited role in conferring antimicrobial resistance among DEC. However, DEC harboring truncated c1-integrons may be resistant to a greater number of antimicrobials than c1-integron-negative DEC, similar to strains harboring intact c1-integrons.Entities:
Year: 2020 PMID: 32090095 PMCID: PMC7013361 DOI: 10.1155/2020/4908189
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1(a) General structure of class 1 integrons (c1-integrons). The red arrows show the positions of primers used for detection of intI1, qacEΔ1, and sul1. The blue arrows show the positions of primers used for sequencing. P indicates the promoter. (b) Intact c1-integron cassette arrays that were confirmed by sequencing of PCR products, along with the corresponding resistance patterns. (c) Truncated c1-integron cassette arrays that were confirmed by next-generation sequencing analysis, along with the corresponding resistance patterns. EAEC: enteroaggregative Escherichia coli; EPEC: enteropathogenic E. coli; STEC: Shiga toxin-producing E. coli; CTX: cefotaxime; SXT: sulfamethoxazole-trimethoprim; (S) streptomycin; (C) chloramphenicol; (K) kanamycin; AM: ampicillin; NA: nalidixic acid; TE: tetracycline; aadA1: aminoglycoside resistance gene; dfrA: dihydrofolate reductase gene (trimethoprim resistance); OUT: O-serogroup-untypeable. All insertion sequences designated “IS1” belong to the IS1 family.
Diarrheagenic Escherichia coli strains used in this study (n = 162).
| Pathogenic categories | No. of strains | Origin | O-serogroup | Isolation year |
|---|---|---|---|---|
| EAEC | 40 | Symptomatic patient ( | 86 ( | 2012–2014 |
| Asymptomatic carrier ( | 44 ( | 2012–2014 | ||
| EPEC | 37 | Symptomatic patient ( | 55 ( | 2012–2014 |
| Asymptomatic carrier ( | 15 ( | 2013-2014 | ||
| STEC | 83 | Symptomatic patient ( | 26 ( | 2012–2014 |
| Asymptomatic carrier ( | 26 ( | 2012–2014 | ||
| ETEC | 2 | Asymptomatic carrier ( | 148 ( | 2013-2014 |
EAEC: enteroaggregative E. coli; EPEC: enteropathogenic E. coli; STEC: Shiga toxin-producing E. coli; ETEC: enterotoxigenic E. coli; OUT: O-serogroup untypeable.
Primers used in this study.
| Target gene | Primer direction | Nucleotide sequence (5′–3′) | Amplicon size (bp) | Reference number |
|---|---|---|---|---|
|
| F | CAGTGGACATAAGCCTGTTC | 160 | 15 |
| R | CCCGAGGCATAGACTGTA | |||
|
| F | CGGCGTGGGCTACCTGAACG | 433 | 15 |
| R | GCCGATCGCGTGAAGTTCCG | |||
|
| F | ATCGCAATAGTTGGCGAAGT | 250 | 15 |
| R | GAAGCTTTTGCCCATGAAGC | |||
| Class 1 gene cassette | F | GGCATCCAAGCAGCAAGC | Variable | 15 |
| R | AAGCAGACTTGACCTGAT | |||
|
| F | GTATACACAAAAGAAGGAAGC | 254 | 10 |
| R | ACAGAATCGTCAGCATCAGC | |||
|
| F | GCTTAGTGCTGGTTTAGGAT | 591 | 10 |
| R | CTCTGCAGATTAACCTCTGC |
Number of antibiotics to which the strains with/without integrons showed resistance.
| Presence of integrons | Intact/truncated integron and pathotype | No. of strains | Number (%) of antibiotics to which each strain showed resistance† | ||||||
|---|---|---|---|---|---|---|---|---|---|
| None | One | Two | Three | Four | Five | Six | |||
| Strains with integrons | Intact integron | ||||||||
| EAEC | 11 | 0 | 1 | 0 | 0 | 5 | 3 | 2 | |
| EPEC | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
| STEC | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | |
| ETEC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Subtotal | 15 | 1 (7%) | 2 (13%) | 0 | 0 | 6 (40%) | 3 (20%) | 3 (20%) | |
| Truncated integron | |||||||||
| EAEC | 9 | 0 | 0 | 0 | 1 | 2 | 5 | 1 | |
| EPEC | 3 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | |
| STEC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ETEC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Subtotal | 12 | 0 | 0 | 0 | 2 (16.7) | 3 (25.0) | 6 (50.0) | 1 (8.3) | |
| Strains without integrons | EAEC | 20 | 6 | 6 | 5 | 1 | 1 | 1 | 0 |
| EPEC | 32 | 25 | 2 | 2 | 1 | 1 | 0 | 1 | |
| STEC | 81 | 66 | 6 | 7 | 1 | 1 | 0 | 0 | |
| ETEC | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | |
| Subtotal | 135 | 97 (71.6) | 15 (11.1) | 14 (10.4) | 3 (2.2) | 3 (2.2) | 2 (1.5) | 1 (0.7) | |
|
| |||||||||
| Total | 162 | 98 (60.5) | 17 (10.5) | 14 (8.6) | 5 (3.1) | 12 (7.4) | 11 (6.8) | 5 (3.1) | |
†A total of 14 antimicrobials were tested (ampicillin, sulfamethoxazole-trimethoprim, tetracycline, nalidixic acid, streptomycin, chloramphenicol, gentamicin, cefotaxime, norfloxacin, kanamycin, ciprofloxacin, fosfomycin, imipenem, and meropenem).
Number (%) of antibiotic-resistant diarrheagenic Escherichia coli isolates in Japan, with/without class 1 integrons.
| Antibiotics | EAEC | EPEC | STEC | ETEC | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Integron + ( | Integron − ( | Total ( | Integron + ( | Integron − ( | Total ( | Integron + ( | Integron − ( | Total ( | Integron + ( | Integron − ( | Integron + ( | Integron − ( | |
| Ampicillin | 20 (100)‡ | 13 (65.0) | 33 (82.5) | 3 (60.0)‡ | 4 (12.5) | 7 (18.9) | 1 (50.0) | 8 (9.9) | 9 (10.8) | 0 | 1 (50.0) | 24 (88.9)‡ | 26 (19.3) |
| Sulfamethoxazole-trimethoprim | 18 (90.0)‡ | 3 (15.0) | 21 (52.5) | 3 (60.0)‡ | 1 (3.1) | 4 (10.8) | 1 (50.0)‡ | 1 (1.2) | 2 (2.4) | 0 | 1 (50) | 22 (81.5)‡ | 6 (4.4) |
| Tetracycline | 18 (90.0)‡ | 3 (15.0) | 21 (52.5) | 3 (60.0)‡ | 4 (12.5) | 7 (18.9) | 1 (50.0) | 9 (11.1) | 10 (12.0) | 0 | 1 (50.0) | 22 (81.5)‡ | 17 (12.6) |
| Nalidixic acid | 13 (65.0)‡ | 3 (15.0) | 16 (40.0) | 2 (40.0) | 3 (9.4) | 5 (13.5) | 0 | 0 | 0 | 0 | 2 (100) | 15 (55.6)‡ | 8 (5.9) |
| Streptomycin | 11 (55.0)‡ | 3 (15.0) | 14 (35.5) | 2 (40.0) | 2 (6.3) | 4 (10.8) | 2 (100)‡ | 6 (7.4) | 8 (9.6) | 0 | 1 (50.0) | 15 (55.6)‡ | 12 (8.9) |
| Chloramphenicol | 6 (30.0) | 1 (5.0) | 7 (17.5) | 2 (40.0) | 2 (6.3) | 4 (10.8) | 1 (50.0)‡ | 1 (1.2) | 2 (2.4) | 0 | 0 | 9 (33.3)‡ | 4 (3.0) |
| Gentamicin | 2 (9.52) | 0 | 2 (5.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (7.4)‡ | 0 |
| Cefotaxime | 1 (10.0) | 2 (10.0) | 3 (7.5) | 0 | 2 (6.3) | 2 (5.4) | 0 | 0 | 0 | 0 | 0 | 1 (3.7) | 4 (3.0) |
| Norfloxacin | 1 (5.0) | 0 | 1 (2.5) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (3.7) | 0 |
| Kanamycin | 0 | 0 | 0 | 1 (20.0) | 1 (3.1) | 2 (5.4) | 1 (50.0) | 2 (2.5) | 3 (3.6) | 0 | 0 | 2 (7.4) | 3 (2.2) |
| Ciprofloxacin, fosfomycin, imipenem, or meropenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phenotype of multidrug resistance† | 19 (95.0)‡ | 2 (10.0) | 21 (52.5) | 4 (80.0)‡ | 3 (9.4) | 7 (18.9) | 1 (50.0) | 2 (2.5) | 3 (3.6) | 0 | 1 (50.0) | 24 (88.9)‡ | 8 (5.9) |
|
|
|
|
|
|
|
|
|
| |||||
†Defined as resistance to three or more classes of antimicrobials. ‡Denotes significantly higher rate of resistance to antibiotics for class 1 integron-positive isolates compared with class 1 integron-negative isolates (p > 0.05).
Comparison between this study and other studies of gene cassettes within class 1 integron.
|
|
Kang et al. (Korea) and Heir et al. (Norway). †Yang et al. (China). ‡Chang et al. (Taiwan), Li et al. (China) and Chowdhury et al. (Argentina, Chile, Uruguay, and Australia). §Peirano et al. (Brazil), Zhang et al. (China), and Krauland et al. (United States, Canada, Argentina, Australia, Belgium, South Africa, Spain, Italy, Denmark, and Taiwan).